Moderna just delivered a classic catalyst-driven rip. Shares of Moderna (NASDAQ: MRNA) jumped hard in live trading after a sharp regulatory reversal put its next big product push back in play: a seasonal flu vaccine that investors have been watching as a key step in Moderna’s post-COVID revenue reset.
At last check, Moderna was trading at $46.73, up $2.80 for a gain of about 6% on the day. The stock’s reaction was tied to fresh headlines that the US Food and Drug Administration reversed its earlier stance and will now review Moderna’s flu vaccine application for mRNA-1010.
What sparked the rally
The market move was triggered by reports that the FDA has agreed to move forward with a review of Moderna’s flu vaccine submission after an earlier rejection. In simple terms, a near-term “no” turned into a “we’ll take another look,” and that shift matters because Moderna’s pipeline narrative has been under pressure while COVID vaccine demand continues to normalize.
Flu is not a side quest. A credible path into seasonal influenza vaccines helps Moderna aim for more repeatable, annual demand — the kind of cadence investors typically reward in large-cap healthcare when execution is clear.
For background on how the FDA evaluates vaccines and related biologics, readers can review the agency’s vaccines and biologics information hub on the FDA website.
MRNA stock today: the numbers traders are watching
Even though the headline drove the move, the tape tells the story investors traded:
Price: $46.73 (up about 6%)
Previous close: $43.93
Open: $46.70
Day’s range: $45.65 to $47.68
Volume: 10,386,112 shares (vs. 11,778,720 average)
Intraday market cap: $18.255B
52-week range: $22.28 to $55.20
Beta (5Y monthly): 1.34
Two quick takeaways stand out. First, the stock gapped higher at the open and largely held that strength, with trades clustered near the upper half of the day’s range. Second, volume was active but not extreme versus its typical pace — a sign the move wasn’t purely a short squeeze, but still leaves room for follow-through if more clarity lands.
Why the FDA reversal is a big deal for Moderna’s story
Moderna remains in a transition period. While the company built enormous recognition and revenue during the COVID era, investors have been forcing a tougher question: what does sustainable growth look like when pandemic demand fades?
The company’s flu program is one of the most closely tracked efforts in that transition. A review path for mRNA-1010 matters because seasonal influenza is a recurring market, and a successful entry can reshape sentiment around Moderna’s medium-term revenue mix.
That doesn’t mean the stock suddenly becomes “safe.” The business is still absorbing a post-pandemic reset, and the financial profile reflects that. Moderna’s trailing earnings remain negative, with EPS (TTM) at -7.26, and the stock can move fast in either direction when regulatory or trial headlines hit.
Where expectations sit now
One data point investors often check after a headline rally is the Street’s baseline target. Moderna’s 1-year target estimate is $41.40, which puts today’s price action above that reference point. When a stock trades above the consensus target, the market is effectively saying, “the old model is stale” — or it’s simply pricing in a higher-risk, higher-volatility outcome.
The next major checkpoint is the company’s next earnings window, with an estimated date shown as April 30, 2026. Traders typically look for any pipeline timing updates, regulatory milestones, and cost discipline signals that either reinforce momentum or cool it down.
The levels that can define the next move
Technically, today’s action resets the short-term conversation. After printing an intraday high near $47.68, the next obvious magnet is the round-number zone around $50, where profit-taking often increases and options activity can intensify.
On the downside, the gap zone matters. If enthusiasm fades, traders often watch whether the stock can stay comfortably above the prior close near $43.93 and whether buyers defend pullbacks before momentum breaks.
What investors should monitor next
For Moderna, catalysts tend to arrive in clusters. After an FDA reversal brings the flu application back into focus, investors typically monitor:
Regulatory timing: whether the review stays on track or hits delays.
Commercial readiness: how Moderna positions its product in a market dominated by entrenched flu vaccine players.
Pipeline confidence: whether progress on respiratory products supports a broader diversification story.
Cost and cash discipline: how aggressively the company manages spending as it bridges to new revenue streams.
For broader market context as traders digest macro catalysts alongside single-stock headlines, you can also read our market coverage here: TSX futures rise as gold and oil rebound as Fed minutes come into focus.
Bottom line: Moderna’s surge is being priced as a renewed opportunity — a regulatory reversal that keeps a key flu vaccine pathway alive. Whether the move becomes a sustained rerating or fades into another headline spike will depend on what comes next from the FDA timeline, Moderna’s execution, and the company’s ability to prove that post-COVID growth can be more than a promise.
